Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: Pharmacodynamic evaluation and comparison with isogenic normal-phenotype and revertant strains

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 4, 2009, Pages 1434-1442

  Anh Nguyen, Hoang ^a   Denis, Olivier ^b   Vergison, Anne ^c   Theunis, Anne ^d   Tulkens, Paul M ^a   Struelens, Marc J ^b   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MOXIFLOXACIN; ORITAVANCIN; OXACILLIN; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL VACUOLE; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE TIME EFFECT RELATION; DRUG EFFECT; HUMAN; HUMAN CELL; LASER MICROSCOPY; MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CELL LINE; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUSIDIC ACID; GENTAMICINS; HUMANS; MACROPHAGES; MICROBIAL SENSITIVITY TESTS; OXACILLIN; PHENOTYPE; PROTEIN BINDING; STAPHYLOCOCCUS AUREUS; THYMIDINE;

EID: 65649094853     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01145-08     Document Type: Article

References (63)

1. Allen, N. E., and T. I. Nicas. 2003. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26:511-532. (Pubitemid 36187412)
2. Amsden, G. W. 2000. Tables of antimicrobial agents pharmacology, p. 635-700. In G. L. Mandeli, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, NY.
3. Arhin, F. F., I. Sarmiento, A. Belley, G. A. McKay, D. C. Draghi, P. Grover, D. F. Sahm, T. R. Parr, Jr., and G. Moeck. 2008. Effect of Polysorbate-80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52:1597-1603.
4. Auwerx, J. 1991. The human leukemia cell line, THP-I: a multifaceted model for the study of monocyte-macrophage differentiation. Experientia 47:22-31. (Pubitemid 21892770)
5. Baltch, A. L., W. J. Ritz, L. H. Bopp, P. Michelsen, and R. P. Smith. 2008. Activities of daptomycin and comparative antimicrobials, singly and in com-bination, against extracellular and intracellular Staphylococcus aureus and its stable small colony variant in human monocyte-derived macrophages and in broth. Antimicrob. Agents Chemother. 52:1829-1833.
6. BaMt, J. M., P. van Langevelde, J. M. Vann, and R. A. Proctor. 1994. Gentamicin-resistant menadione and hemin auxotrophic Staphylococcus aureus persist within cultured endothelial cells. J. Infect. Dis. 170:1033-1037. (Pubitemid 24296593)
7. Barcia-Macay, M., S. Lemaire, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Evaluation of the extracellular and intracellular activities (human THP-I macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermedi-ate and vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Che-mother. 58:1177-1184.
8. Barcia-Macay, M., F. Mouaden, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2008. Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts). J. Antimicrob. Chemother. 61:1288-1294.
9. Barcia-Macay, M., C. Serai, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke. 2006. Pharmacodynamic evaluation of the intracellular activ-ities of antibiotics against Staphylococcus aureus in a model of THP-I mac-rophages. Antimicrob. Agents Chemother. 50:841-851. (Pubitemid 43327786)
10. Baumert, N., C. von Eiff, F. Schaaff, G. Peters, R.A. Proctor, and H. G. Sahl. 2002. Physiology and antibiotic susceptibility oí Staphylococcus aureus small colony variants. Microb. Drug Resist. 8:253-260. (Pubitemid 36043690)
11. Belley, A., B. Harris, T. Beveridge, T. R. Parr, Jr., and G. Moeck. 2008. Cell wall and membrane effects of oritavancin on Staphylococcus aureus and Enterococcus faecalis, abstr. P537. Abstr. 18th Eur. Cong. Clin. Microbiol. Infect. Dis., Barcelona, Spain, 19 to 22 April 2008.
12. Besier, S., C. Smaczny, C. von Mallinckrodt, A. Krahl, H. Ackermann, V. Brade, and T. A. Wichelhaus. 2007. Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease. J. Clin. Microbiol. 45:168-172. (Pubitemid 46127347)
13. Besier, S., J. Zander, B. C. Kahl, P. Kraiczy, V. Brade, and T. A. Wichelhaus. 2008. The thymidine-dependent small colony variant phenotype is associated with hypermutability and antibiotic resistance in clinical Stapltylococcus au-reus isolates. Antimicrob. Agents Chemother. 52:2183-2189.
14. Besier, S., J. Zander, E. Siegel, S. H. Saum, K. P. Hunfeld, A. Ehrhart, V. Brade, and T. A. Wichelhaus. 2008. Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease. J. Clin. Microbiol. 46:3829-3832.
15. Carryn, S., V. d. Van, F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Impairment of growth oí Listeria monocytogenes in THP-I macrophages by granulocyte macrophage colony-stimulating factor: release of tumor necrosis factor-alpha and nitric oxide. J. Infect. Dis. 189:2101-2109. (Pubitemid 38692292)
16. Chambers, H. F. 2000. Penicillins, p. 281-293. In G. L. Mandeli, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, NY. (Pubitemid 19113671)
17. Chatterjee, L, M. Herrmann, R. A. Proctor, G. Peters, and B. C. Kahl. 2007. Enhanced post-stationary-phase survival of a clinical thymidine-dependent small-colony variant of Staphylococcus aureus results from lack of a func-tional tricarboxylic acid cycle. J. Bacteriol. 189:2936-2940. (Pubitemid 46556079)
18. Chatterjee, L, A. Kriegeskorte, A. Fischer, S. Deiwick, N. Theimann, R. A. Proctor, G. Peters, M. Herrmann, and B. C. Kahl. 2008. In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine de-pendency in clinical small-colony variants of Staphylococcus aureus. J. Bac-teriol. 190:834-842.
19. Chuard, C, P. E. Vaudaux, R. A. Proctor, and D. P. Lew. 1997. Decreased susceptibility to antibiotic killing of a stable small colony variant of Staphy-lococcus aureus in fluid phase and on fibronectin-coated surfaces. J. Antimi-crob. Chemother. 39:603-608. (Pubitemid 27236878)
20. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing, 18th informational supplement. Approved standard M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Denis, O., A. Deplano, R. De Ryck, C. Xonhoff, and M. J. Struelens. 2003. Emergence and spread of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus in Belgian hospitals. Microb. Drug Resist. 9:61-71. (Pubitemid 36403059)
22. Denis, O., A. Deplano, C. Xonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonça, and M. J. Struelens. 2006. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-re-sistant Staphylococcus aureus strains from a national survey of Belgian hos-pitals. Antimicrob. Agents Chemother. 50:2680-2685. (Pubitemid 44198687)
23. Hallin, M., O. Denis, A. Deplano, R. De Mendonça, R. De Ryck, S. Rottiers, and M. J. Struelens. 2007. Genetic relatedness between methicillin-suscep-tible and methicillin-resistant Staphylococcus aureus: results of a national survey. J. Antimicrob. Chemother. 59:465-472. (Pubitemid 47073452)
24. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multi-functional lipoglycopeptide, disrupts both cell wall synthesis and cell mem-brane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134. (Pubitemid 40327734)
25. Kahl, B., M. Herrmann, A. S. Everding, H. G. Koch, K. Becker, E. Harms, R. A. Proctor, and G. Peters. 1998. Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J. In-fect. Dis. 177:1023-1029. (Pubitemid 28155157)
26. Kahl, B. C, G. Belling, P. Becker, I. Chatterjee, K. Wardecki, K. Hilgert, A. L. Cheung, G. Peters, and M. Herrmann. 2005. Thymidine-dependent Staphylococcus aureus small-colony variants are associated with extensive alterations in regulator and virulence gene expression profiles. Infect. Im-mun. 73:4119-4126. (Pubitemid 40923153)
27. Kahl, B. C, G. Belling, R. Reichelt, M. Herrmann, R. A. Proctor, and G. Peters. 2003. Thymidine-dependent small-colony variants of Staphylococcus aureus exhibit gross morphological and ultrastructural changes consistent with impaired cell separation. J. Clin. Microbiol. 41:410-413. (Pubitemid 36098608)
28. Kipp, F., B. C. Kahl, K. Becker, E. J. Baron, R. A. Proctor, G. Peters, and C. von EiEf. 2005. Evaluation of two chromogenic agar media for recovery and identification of Staphylococcus aureus small-colony variants. J. Clin. Micro-biol. 43:1956-1959. (Pubitemid 40491253)
29. Lee, S. Y., H. W. Fan, J. L. Kuti, and D. P. Nicolau. 2006. Update on daptomycin: the first approved lipopeptide antibiotic. Expert. Opin. Fhar-macother. 7:1381-1397.
30. Lemaire, S., K. Kosowska-Shick, K. Julian, P. M. Tulkens, F. Van Bambeke, and P. C. Appelbaum. 2008. Activities of antistaphylococcal antibiotics to-wards the extracellular and intraphagocytic forms of 5. aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin. Microbiol. Infect. 14:766-777.
31. Lemaire, S., A. Olivier, F. Van Bambeke, P. M. Tulkens, P. C. Appelbaum, and Y. Glupczynski. 2008. Restoration of susceptibility of intracellular me-thicillin-resistant Staphylococcus aureus to ß-lactams: comparison between strains, cells, and antibiotics. Antimicrob. Agents Chemother. 52:2797-2805.
32. Lemaire, S., F. Van Bambeke, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2005. Activity of three ß-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904. (Pubitemid 40883174)
33. Leuthner, K. D., J. R. Aeschlimann, and M. J. Rybak. 2005. Quinupristin/ dalfopristin, p. 367-382. In V. L. Yu, G. Edwards, P. S. McKinnon, C. Peloquin, and G. D. Morse (ed.), Antimicrobial therapy and vaccines. Esun Technologies, LLC, Pittsburgh, PA.
34. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343. (Pubitemid 44294945)
35. Maes, N., J. Magdalena, S. Rottiers, Y. De Gheldre, and M. J. Struelens. 2002. Evaluation of a triplex PCR assay to discriminate Staphylococcus au-reus from coagulase-negative staphylococci and determine methicillin resis-tance from blood cultures. J. Clin. Microbiol. 40:1514-1517. (Pubitemid 34279929)
36. McKay, G. A., I. Fadhil, S. Beaulieu, S. Ciblât, A. R. Far, G. Moeck, and Parr, T. R., Jr. 2006. Oritavancin disrupts transmembrane potential and membrane integrity concomitantly with cell killing in Staphylococcus aureus and vancomycin-resistant enterococci. Abstr. 46th Intenci. Conf. Antimi-crob. Agents Chemother., abstr. Cl-682.
37. Mitchell, G., C. A. Lamontagne, E. Brouillette, G. Grondin, B. G. Talbot, M. Grandbois, and F. Malouin. 2008. Staphylococcus aureus SigB activity pro-motes a strong fibronectin-bacterium interaction which may sustain host tissue colonization by small-colony variants isolated from cystic fibrosis pa-tients. MbI. Microbiol. 70:1540-1555.
38. Moisan, H., E. Brouillette, C. L. Jacob, P. Langlois-Begin, S. Michaud, and F. Malouin. 2006. Transcription of virulence factors in Staphylococcus aureus small-colony variants isolated from cystic fibrosis patients is influenced by SigB. J. Bacteriol. 188:64-76.
39. National Committee for Clinical Laboratory Standards. 1998. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26A. National Committee for Clinical Laboratory Standards, Wayne, PA.
40. Proctor, R. A., and G. Peters. 1998. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. Clin. Infect. Dis. 27:419-422. (Pubitemid 28375861)
41. Proctor, R. A., P. van Langevelde, M. Kristjansson, J. N. Maslow, and R. D. Arbeit. 1995. Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin. Infect. Dis. 20:95-102. (Pubitemid 26066632)
42. Proctor, R. A., C. von Eiff, B. C. Kahl, K. Becker, P. McNamara, M. Her-rmann, and G. Peters. 2006. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat. Rev. Microbiol. 4:295-305.
43. Proctor, R. A., and A. von Humboldt. 1998. Bacterial energetics and antimi-crobial resistance. Drug Resist. Updat. 1:227-235.
44. Sadowska, B., A. Bonar, C. von Eiff, R. A. Proctor, M. Chmiela, W. Rud-nická, and B. Rozalska. 2002. Characteristics of Staphylococcus aureus, iso-lated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol. Med. Microbiol. 32:191-197. (Pubitemid 34270509)
45. Sendi, P., M. Rohrbach, P. Graber, R. Frei, P. E. Ochsner, and W. Zimmerli. 2006. Staphylococcus aureus small colony variants in prosthetic joint infec-tion. Clin. Infect. Dis. 43:961-967. (Pubitemid 44631093)
46. Serai, C, F. Van Bambeke, and P. M. Tulkens. 2003. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. Antimicrob. Agents Chemother. 47:2283-2292. (Pubitemid 36753584)
47. Stein, G. E., and W. A. Craig. 2006. Tigecycline: a critical analysis. Clin. Infect. Dis. 43:518-524. (Pubitemid 44157163)
48. Tsuji, B. T., G. W. Kaatz, and M. J. Rybak. 2005. Linezolid and other oxazolidinones, p. 223-241. In V. L. Yu, G. Edwards, P. S. McKinnon, C. Peloquin, and G. D. Morse (ed.), Antimicrobial therapy and vaccines. Esun Technologies, LLC, Pittsburgh, PA.
49. Tsuji, B. T., S. N. Leonard, P. R. Rhomberg, R. N. Jones, and M. J. Rybak. 2008. Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or se mm. Diagn. Microbiol. Infect. Dis. 60:441-444.
50. Van Bambeke, F., M. Barcia-Macay, S. Lemaire, and P. M. Tulkens. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9:218-230.
51. Van Bambeke, F., S. Carryn, C. Serai, H. Chanteux, D. Tyteca, M. P. Mingeot-Leclercq, and P. M. Tulkens. 2004. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48: 2853-2860. (Pubitemid 38989146)
52. Van Bambeke, F., Y. Van Laethem, P. Courvalin, and P. M. Tulkens. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936. (Pubitemid 38608472)
53. Van de Velde, S., H. A. Nguyen, F. Van Bambeke, P. M. Tulkens, J. Grellet, V. Dubois, C. Quentin, and M. C. Saux. 2008. Contrasting effects of human THP-I cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcus aureus and Listeria mono-cytogenes. J. Antimicrob. Chemother. 62:518-521.
54. Vannuffel, P., and C. Cocito. 1996. Mechanism of action of streptogramins and macrolides. Drugs 51(Suppl. 1):20-30. (Pubitemid 126665193)
55. Vaudaux, P., P. Francois, C. Bisognano, W. L. Kelley, D. P. Lew, J. Schrenzel, R. A. Proctor, P. J. McNamara, G. Peters, and C. von Eiff. 2002. Increased expression of clumping factor and fibronectin-binding proteins by hemB mutants of Staphylococcus aureus expressing small colony variant phe-notypes. Infect. Immun. 70:5428-5437.
56. Vaudaux, P., W. L. Kelley, and D. P. Lew. 2006. Staphylococcus aureus small colony variants: difficult to diagnose and difficult to treat. Clin. Infect. Dis. 43:968-970. (Pubitemid 44631094)
57. Vergison, A., O. Denis, A. Deplano, G. Casimir, G. Claeys, F. DeBaets, K. DeBoeck, N. Douât, H. Franckx, J. Gigi, M. leven, C. Knoop, P. Lebeque, F. Lebrun, A. Malfroot, F. Paucquay, D. Pierard, J. Van Eldere, and M. J. Struelens. 2007. National survey of molecular epidemiology of Staphylococ-cus aureus colonization in Belgian cystic fibrosis patients. J. Antimicrob. Chemother. 59:893-899. (Pubitemid 47073360)
58. von Eiff, C. 2008. Staphylococcus aureus small colony variants: a challenge to microbiologists and clinicians. Int. J. Antimicrob. Agents 31:507-510.
59. von Eiff, C, K. Becker, D. Metze, G. Lubritz, J. Hockmann, T. Schwarz, and G. Peters. 2001. Intracellular persistence of Staphylococcus aureus small-colony variants within keratinocytes: a cause for antibiotic treatment failure in a patient with Dariers disease. Clin. Infect. Dis. 32:1643-1647. (Pubitemid 32458736)
60. von Eiff, C, D. Bettin, R. A. Proctor, B. Rolauffs, N. Lindner, W. Winkel-mann, and G. Peters. 1997. Recovery of small colony variants of Staphylo-coccus aureus following gentamicin bead placement for osteomyelitis. Clin. Infect. Dis. 25:1250-1251. (Pubitemid 27513223)
61. von Eiff, C, C. Heilmann, R. A. Proctor, C. Woltz, G. Peters, and F. Götz. 1997. A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly. J. Bacteriol. 179:4706-4712. (Pubitemid 27339714)
62. von Eiff, C, G. Peters, and K. Becker. 2006. The small colony variant (SCV) concept: the role of staphylococcal SCVs in persistent infections. Injury 37(Suppl. 2):S26-S33.
63. Zander, J., S. Besier, S. H. Saum, F. Dehghani, S. Loitsch, V. Brade, and T. A. Wichelhaus. 2008. Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect. Immun. 76: 1333-1339.